

1 Performance of At-Home Self-Collected Saliva and Nasal-Oropharyngeal Swabs in the
2 Surveillance of COVID-19

3

4 Running Title: At-Home Self-Collected Samples in COVID-19 Diagnosis

5

6 Paulo H. Braz-Silva,^{a,b*} Ana C. Mamana,^a Camila M. Romano,^a Alvina C. Felix,^a

7 Anderson V. de Paula,^a Noeli E. Ferreira,^a Lewis F. Buss,^a Tania R. Tozetto-Mendoza,^a

8 Rafael A. V. Caixeta,^b Fabio E. Leal,^c Regina M. Z. Grespan,^c João C. S. Bizário,^c Andrea

9 B. C. Ferraz,^c Dipak Sapkota,^d Simone Giannecchini,^e Kelvin K. To,^{f,g,h} Alain Doglio,ⁱ

10 Maria C. Mendes-Correa^a

11 *a. Laboratory of Virology (LIM-52), Institute of Tropical Medicine of São Paulo, School of Medicine,*
12 *University of São Paulo, São Paulo, Brazil*

13 *b. Department of Stomatology, School of Dentistry, University of Sao Paulo, Sao Paulo, Brazil*

14 *c. Municipal University of São Caetano do Sul, São Caetano do Sul, Brazil*

15 *d. Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway*

16 *e. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy*

17 *f. State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu*
18 *Centre for Infection, Li KaShing Faculty of Medicine of the University of Hong Kong, Special*
19 *Administrative Region, China*

20 *g. Department of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region,*
21 *China*

22 *h. Department of Clinical Microbiology and Infection Control, The University of Hong Kong –*
23 *Shenzhen Hospital, Shenzhen, China*

24 *i. Laboratory MICORALIS (Microbiologie Orale, Immunité et Santé) School of Dentistry,*
25 *University of Côte d'Azur, Nice, France*

26 *** Corresponding author:**

27 Paulo H. Braz-Silva, DDS, PHD

28 Laboratório de Virologia - Instituto de Medicina Tropical de São Paulo – FMUSP

29 Av. Dr. Enéas Carvalho de Aguiar, 470 - Jardim America, São Paulo – Brazil - 05403-000

30 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **ABSTRACT**

32 SARS-CoV-2 quickly spread in the worldwide population by contact with oral and
33 respiratory secretions of infected individuals, imposing social restrictions to control the
34 infection. Massive testing is essential to breaking the chain of COVID-19 transmission.
35 The aim of this study was to compare the performance of at-home self-collected samples
36 - saliva and combined nasal-oropharyngeal swabs (NOP) - for SARS-CoV-2 detection in
37 a telemedicine platform for COVID-19 surveillance. We analyzed 201 patients who met
38 the criteria of suspected COVID-19. NOP sampling were combined (nostrils and
39 oropharynx) and saliva collected using a cotton pad device. Detection of SARS-COV-2
40 was performed by using the Altona RealStar® SARS-CoV-2 RT-PCR Kit 1.0. According
41 to our data, there was an overall significant agreement (κ coefficient value of 0.58)
42 between the performances of saliva and NOP. Assuming that positive results in either
43 sample represent true infections, 70 patients positive for SARS-CoV-2 were identified,
44 with 52/70 being positive in NOP and 55/70 in saliva. This corresponds to sensitivities of
45 74.2% (95% CI; 63.7% to 83.1%) for NOP and 78.6% (95% CI; 67.6% to 86.6%) for
46 saliva. We also found a strong correlation (β -coefficients < 1) between the cycle threshold
47 values in saliva and NOP. Ageusia was the only symptom associated with patients SARS-
48 CoV-2 positive only in NOP ($p=0.028$). In conclusion, our data show the feasibility of
49 using at-home self-collected samples (especially saliva), as an adequate alternative for
50 SARS-CoV-2 detection. This new approach of testing can be useful to develop strategies
51 for COVID-19 surveillance and for guiding public health decisions.

52

53 **Keywords:** Saliva; Coronavirus; PCR; Primary Health Care; Infection Control;
54 Telemedicine

55

56 INTRODUCTION

57 Rapid and accurate diagnostic tests are essential for controlling the SARS-CoV-2
58 pandemic. Nevertheless, biological specimen collection is an important logistic challenge
59 to provide massive testing(1-3). The possibility to use self-collected samples for COVID-
60 19 testing offers several advantages, especially to minimize the risk of exposing
61 healthcare workers to the virus, since self-collection does not require direct involvement
62 of trained personnel in the sample collection(4, 5). Recently publications have been
63 showed a similar sensitivity between saliva samples and nasal swabs collected by health-
64 workers and those collected by a patient for COVID-19 molecular diagnosis, thus
65 providing an important background for the choice of this strategy for surveillance of
66 COVID-19(6-8).

67 Saliva has been described as a good alternative for SARS-CoV-2 detection,
68 showing additional advantages compared to swab collection(9-12). Saliva collection does
69 not cause discomfort or nasal bleeding to patients, does not require swab collectors or
70 personal protective equipment, which are currently in short-supply in the market(3). In
71 addition, saliva allows examination of several biomarkers, which could be useful as
72 molecular signatures for patient stratification regarding infection severity(10, 13, 14).

73 In a pandemic scenario, at-home self-collection of samples plays a key role in the
74 surveillance and control of the infection by allowing the patient with clinical suspicion of
75 COVID19 to have access to proper healthcare and quick isolation of the confirmed
76 cases(4, 5). Recently published studies show that 80-85% of individuals infected with
77 SARS-CoV-2 have few or no symptoms, while 15-20% develop more severe disease,
78 often associated with advanced age or other co-morbidities(15).

79 The Corona São Caetano program is a primary care initiative providing specific
80 home care to all residents of São Caetano do Sul, state of São Paulo, Brazil. This program

81 started in April 2020 due to the increasing number of COVID-19 cases in the country.
82 Self-collection of nasal-oropharyngeal swabs has been used to obtain samples for
83 diagnosis since the beginning of the epidemics, with excellent results, as hospitalization
84 rate was less than 3% among the patients enrolled in the program(16).

85 The aim of this study was to compare the performance of two different at-home
86 self-collected samples - saliva and combined nasal-oropharyngeal swabs (NOP) - for
87 COVID-19 molecular diagnosis in the community patients outside the healthcare
88 facilities.

89

90 **PATIENTS AND METHODS**

91 The present study was developed in a telemedicine platform for COVID-19
92 surveillance called “Corona São Caetano”. Residents of the municipality aged 12 years
93 or older who had suspected symptoms were encouraged to contact the program via
94 website or by phone. They were invited to complete a screening questionnaire including
95 socio-demographic data, information on type, onset and duration of the symptoms.

96 In the last two weeks of May 2020, a serie of 201 consecutive patients
97 participating to the program were included in the present study. The patients met the
98 defined criteria of suspected COVID-19 (i.e., having at least two of the following
99 symptoms: fever, cough, sore throat, coryza or change in/loss of smell [anosmia]; or one
100 of these symptoms plus at least two other symptoms consistent with COVID-19) were
101 further evaluated. These patients were then called by a healthcare professional in order to
102 complete a risk assessment. All pregnant women and patients meeting pre-defined
103 screening criteria for severe disease were advised to attend a hospital service. All the
104 other patients were offered a home visit for self-collection of saliva and NOP samples.

105 Patients testing RT-PCR positive for SARS-CoV-2 were followed up for 14 days
106 (a maximum of 7 phone calls) after completion of their initial questionnaire, whereas

107 those testing negative were followed up in the primary healthcare program. The patients
108 were asked to contact the platform for a new consultation if they developed new
109 symptoms.

110 This study was conducted according to ethical standards defined by institutional
111 and national research ethics committees and the Helsinki Declaration of 1964, including
112 subsequent amendments or comparable ethical standards, and approved by the Clinics
113 Hospital Research Ethics Committee of the University of São Paulo School of Medicine
114 under protocol number 3.979.632. Informed consent was obtained from all the individuals
115 enrolled in this study. This study was designed conform to STROBE Guidelines.

116

117 **Sample Collection**

118 NOP sampling were combined (both nostrils and oropharynx) using commercial
119 flocked swabs with plastic applicators (Goodwood medical care Ltd., Jinzhou, China).
120 Saliva samples were collected using a cotton pad device - Salivette™ (SARSTEDT AG
121 & CO. KG, Nümbrecht, Germany). In order to provide guidance on self-collection
122 procedures, a link to an instructional video was sent to each participant before the home
123 visit. Briefly, patients were instructed to use the swabs in both nostrils and posterior
124 region of the mouth and put both swabs into a tube containing saline solution. For saliva
125 collection, they were instructed to chew carefully a cotton pad for one minute and put it
126 into a specific tube. The samples were collected during the morning hours and the
127 participants were instructed to avoid eating, drinking or toothbrushing at least one hour
128 before the saliva collection. In accordance with the Corona São Caetano Program
129 procedures, samples were immediately put in a cool box (2-8°C) and stored at 4°C in a
130 fridge until shipment to the lab by a specialized carrier in the afternoon the same day.

131

132 **RNA Extraction and Real Time PCR**

133 To recover the saliva from the devices, the tubes were centrifuged at 5,000g for 5
134 minutes. Total nucleic acid was extracted from 200 µl of the saline solution containing
135 NOP and recovered saliva by using the NucliSENS EasyMag (BioMérieux, Durham,
136 North Carolina, USA) automated DNA/RNA extraction platform.

137 Detection of SARS-COV-2 RNA was performed by using the Altona RealStar®
138 SARS-CoV-2 RT-PCR Kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany) which
139 employs a B-COV specific probe directed to gene E and a SARS-COV-2-specific probe
140 directed to gene S. Results were considered positive when one or both genes were
141 amplified with a cycle threshold (Ct) < 40.

142

143 **Statistical Analysis**

144 Cohen's kappa coefficient (κ) was used to measure agreement between RT-PCR-
145 based detection of SARS-COV-2 in saliva and NOP swabs. The sensitivity of each
146 method was calculated assuming that positive cases in either sample type represented true
147 positives, with 95% confidence intervals being calculated by using the exact method.

148 Next, we defined four analytic groups as follows: NOP-/saliva- (G1); NOP-
149 /saliva+ (G2); NOP+/saliva- (G3); NOP+/saliva+ (G4). In order to identify clinical
150 features associated with positivity in NOP and saliva, we specifically compared groups
151 G2 to G4, G3 to G4, and G2 to G3. We used chi-squared test and Wilcoxon's rank-sum
152 test to compare clinical features (i.e. age, gender, symptoms and onset of illness) between
153 the patients in these groups.

154 We then explored the relationship between RT-PCR cycle threshold (Ct) and
155 sample type. We first analyzed group G4 (NOP+/saliva+) and assessed the association
156 between Ct values by using the simple linear regression. Differences in the distribution

157 of Ct values using NOP and saliva were assessed with paired Wilcoxon's rank-sum test.
158 We also assessed the association between time from symptom onset and collection of
159 saliva and NOP by using the simple linear regression. Statistical significance was set at
160 0.05. All analyses were performed by using the R Statistical Software, version 3.6.3.

161

162 **RESULTS**

163 For the current study, 201 consecutive patients participating to the Corona São
164 Caetano program and who met the suspected COVID-19 case definition were included.
165 RT-PCR- based COVID-19 testing was performed in samples from NOP and saliva and
166 results are shown in Table 1.

167 Overall, 16,4 % (33/201) of the results were discordant giving a moderate
168 agreement between the both sampling methods with a Cohen's kappa coefficient of 0.58.
169 Overall, assuming that positive test results in either sample type represent true infections
170 around 35% of patients (n =70) were identified to be positive with COVID-19, while 26
171 % (n = 52) and 27 % (n = 55) were positive based on NOP or saliva detection,
172 respectively. This corresponds to sensitivities of 74.2% (95% CI; 63.7% to 83.1%) for
173 NOP and 78.6% (95% CI; 67.6% to 86.6%) for saliva samples. Of note, 9% (n=18) and
174 7% (n=15) resulted saliva or NOP single positive, respectively.

175

176 **Associations between Clinical Features and SARS-CoV-2 Positivity in Saliva and** 177 **NOP samples using RNA RT-PCR**

178 To investigate relationship between SARS-CoV-2 status in NOP and saliva and
179 demographic and clinical features, patients were categorized in 4 groups (G1 to G4)
180 (Table 2) ; NOP and saliva SARS-CoV-2 negative patients were grouped in G1 (NOP-
181 /saliva-, n = 131); NOP-/saliva+ patients in G2 (n = 18); NOP+/saliva- in G3 (n = 15) and
182 NOP+/saliva+ in G4 (n= 37). We didn't found any significant relationship regarding the

183 demographic data of patients in the different groups, although the sex ratio may be
184 different in G2 as compared to G4. Also, no significant correlation was found regarding
185 clinical symptoms, only ageusia appears to be more prevalent in patients with positivity
186 of SARS-CoV-2 in NOP ($p = 0.028$). Interestingly, the delay between clinical symptoms
187 onset and time of sample collection was significantly shorter ($p < 0.05$) in G2 as compared
188 to G3 and G4, suggesting that patients with simultaneous SARS-CoV-2 positivity in NOP
189 and saliva (G4-patients) were more prompt to quickly display clinical symptoms (Table
190 2).

191 192 **RT-PCR Cycle Thresholds in Saliva and NOP Samples**

193 In order to investigate the relationship between RT-PCR cycle threshold (Ct) and
194 sample type (saliva or NOP), we first compared the Ct values from G4 (NOP+/saliva+, n
195 =37) and assessed the association between Cts using simple linear regression. We found
196 a strong correlation between the Ct values in saliva and naso/oropharyngeal samples
197 (Figure 1). The coefficients of the regression lines (β) were 0.79 ($p < 0.001$) and 0.74 (p
198 = 0.002) for E and S genes, respectively. A β -coefficient < 1 indicated that, in patients
199 with SARS-CoV-2 positivity in NOP and saliva (G4), Cts tended to be higher in saliva
200 than in NOP (also see Figure 2A).

201 Next, we compared the Ct values between the groups G3 (NOP+/saliva-) and G4
202 (NOP+/saliva+). It was observed that the cycle threshold values were lower in patients
203 positive in both NOP and saliva samples (median [IQR], 21.5 [19 - 27]) compared to
204 those positive only in NOP samples (29 [25 - 33], $P = 0.01$, Wilcoxon's rank-sum test)
205 for gene E. Moreover, these results were for gene S (Figure 2B).

206
207
208

209 **Relationship between timing of sample collection and SARS-CoV-2 detection**

210 Because timing of sample collection is a critical parameter of SARS-CoV-2
211 diagnosis, we further investigate the possible relationship between NOP and saliva
212 SARS-CoV-2 detection and the delay between clinical symptom onset and timing of
213 sample collection. Although Ct values tended to be higher at later periods from the onset
214 of symptoms, this did not reach statistical significance (Figure 3).

215

216 **DISCUSSION**

217

218 We prospectively analyzed a cohort of patients with mild symptoms of COVID-
219 19 to assess the diagnostic performance of at-home self-collection of combined naso-
220 oropharyngeal swabs (NOP) and saliva samples.

221 According to our data, there was an overall significant agreement (κ coefficient
222 value of 0.58) between the performances of saliva and NOP samples in the diagnosis of
223 COVID-19. Assuming that positive results in either sample type represent true infections,
224 a total of 70 patients positive for SARS-CoV-2 were identified, with 52/70 being positive
225 in NOP and 55/70 in saliva. This corresponds to sensitivities of 74.2% (95% CI; 63.7%
226 to 83.1%) for NOP and 78.6% (95% CI; 67.6% to 86.6%) for saliva samples. We also
227 found a strong correlation (β -coefficients < 1) between the cycle threshold (Ct) values in
228 saliva and NOP samples. However, the Ct values for the studied genes tended to be higher
229 in saliva than in NOP samples.

230 The use of saliva to detect SARS-CoV-2 has been extensively analyzed by
231 different authors, showing that saliva can be used as an alternative sample to
232 nasopharyngeal swabs for COVID-19 molecular diagnosis(9, 10). The sensitivity found
233 in their studies varied from 81% to 100%(11, 12, 17-21). The majority of the studies were
234 conducted with hospitalized patients presenting more severe clinical forms of the disease,

235 or patients attending a health care unit. It is important to highlight that even with a
236 different population and different saliva collection (i.e. cotton pad device), we found
237 similar sensitivity values.

238 To the best of our knowledge, the present study is the first one in the literature to
239 prospectively examine the performance of at-home self-collected saliva and NOP, in a
240 telemedicine based platform for COVID-19 surveillance. This is highly desirable in a
241 pandemic scenario as it contributes to minimizing the risk of infection transmission in
242 these settings. Additionally, it significantly reduces the workload burden of the healthcare
243 units.

244 According to our results there was a moderate, but very significant, agreement (κ
245 coefficient value of 0.58) between the performances of both sampling methods (NOP and
246 saliva) in the diagnosis of COVID-19. This good overlap between both specimen types
247 was in line with others studies where in general the agreement rate observed varied from
248 0.45 to 1(11, 22). In our study for around 16% of patients, RT-PCR results gave
249 discordant results between both sampling methods. This variation in agreement may be
250 associated with different factors, such as clinical characteristics of the population,
251 diagnostic kits, saliva collection methods, among others. However, these inconsistent
252 results are likely to be related to the fact the virus can reach oral and nasopharyngeal area
253 with different kinetics being not always present at the same time in both sites as
254 previously reported(23).

255 It has been postulated that there is a minimum of three different pathways for
256 SARS-CoV-2 to reach the saliva: firstly, from the lower and upper respiratory tract;
257 secondly, presence in the blood and gingival crevicular fluid; and thirdly, through salivary
258 gland infection, with subsequent release of viral particles into the saliva via salivary
259 ducts(10, 24, 25). It is believed that the highest viral concentration observed in saliva is

260 derived from the respiratory tract(12). Therefore, the finding of viruses in saliva would
261 be expected only in cases with a higher viral load, since the viral particles observed in the
262 saliva also depends on the amount of viruses coming from the respiratory tract. However,
263 the fact that in our study 9% of the samples were positive in saliva in absence of NOP
264 positivity could be indicative that at least in a minimal part the virus comes from salivary
265 origin.

266 In addition, based on the 37 patients positive in both saliva and NOP samples,
267 we found a strong correlation between cycle threshold (Ct) values in saliva and those in
268 NOP samples, indicating that Ct values tended to be higher in saliva than in NOP samples
269 (β -coefficients < 1). When we compared the cases positive in both methods to those
270 positive in NOP only, it was found that Ct values were lower in the first group. This
271 finding reinforces the idea that the viral load has to be higher (lower Ct) in order to be
272 positive in the saliva. Clearly, according to our results, the viral load influenced the
273 results. Only cases with a higher viral load (lower Ct) were positive in both methods,
274 whereas cases with higher Ct values were positive in NOP samples only.

275 Some studies have compared the viral load between nasopharyngeal swab and
276 saliva samples, showing a tendency for a higher viral load (or lower Cts) in
277 nasopharyngeal swabs(10, 19). The severity of the cases included and the time elapsed
278 between collection of material and onset of symptoms are essential information to
279 interpret correctly these results, since the sensitivity of the diagnostic methods varies
280 according to these variables.

281 When we compared the chance of identifying the virus in saliva and NOP samples
282 in relation to the time interval between onset of symptoms and sample collection time, it
283 was observed that the identification of the virus in both samples were associated with a
284 shorter interval of time. These results stress the importance of early diagnosis of COVID-

285 19, in which sample should be collected within the first days of symptoms, thus
286 minimizing the loss of sensitivity of the molecular diagnosis(26). Different studies have
287 analyzed the SARS-CoV-2 shedding in different biologic specimens, reporting that viral
288 loads from upper respiratory tract samples peak within a week of symptom onset and
289 follow a relatively consistent downward trajectory(27). Viral load in other biologic
290 specimens, including saliva, follows the same trajectory(28). However, according to these
291 studies, viral load does not seem to be as high as that observed in respiratory tract samples.
292 Therefore, our findings are in line with these observations.

293 Chemosensory deficits associated with SARS-CoV-2 infection are quite frequent
294 among patients with mild or moderate disease, considered a very early symptom.
295 Interestingly, in our study ageusia was the only symptom statistically associated with
296 patients SARS-CoV-2 positive only in NOP samples (G3; $p=0.028$). This results
297 corroborate with the role of the neurotropic and neuro-invasive characteristics of
298 coronaviruses in the pathogenesis of ageusia, more than a local infection of the gustatory
299 buds(29).

300 Recent studies comparing samples collected by a specialized health-workers and
301 self-collected by the patients for COVID-19 molecular diagnosis showed that both
302 methods had similar sensitivity, which highlights the reliability of self-collection as a
303 public health strategy for COVID-19 surveillance(6-8). Our results corroborate these
304 findings as they showed that both self-collected samples had good sensitivity, especially
305 the saliva, with 78.6% (95% CI; 67.6% to 86.6%).

306 The present study showed that self-collection of saliva and NOP for diagnosis of
307 COVID-19 is feasible in the studied population. Given the similar sensitivities of saliva
308 and NOP samples for detection of SARS-CoV-2 in patients with mild symptoms, it is
309 expected that self-collection of either sample can be valuable in the surveillance of

310 COVID-19 at a population level(30). Moreover by simplifying the procedure and, above
311 all, avoiding the need for the patient to go to a specialized laboratory, this innovative
312 approach can improve COVID-19 diagnosis, notably allowing the sample to be collected
313 as soon as possible after appearance of the first symptoms. However, in this sense, the
314 ease of collection and feasibility for examination of molecular biomarkers for disease
315 stratification and prognosis justify the use of self-collected saliva as a preferred biological
316 sample(2, 26).

317 As the main limitation of this study, we can cite the non-inclusion of
318 asymptomatic individuals in the platform of COVID-19 surveillance.

319 In conclusion, our data show the possibility of using at-home self-collected
320 samples (especially saliva), as an adequate alternative for SARS-CoV-2 detection. This
321 new approach of testing can be useful to develop strategies for COVID-19 surveillance
322 and for guiding public health decisions.

323

324 **Author Contributions**

325 P.H. Braz-Silva, M. C. Mendes-Correa contributed to conception and study design,
326 analysis and interpretation of data, drafted and critically revised the manuscript; A.C.
327 Mamana, C. M. Romano, L. F. Buss contributed to study design, acquisition, analysis,
328 and interpretation of data, drafted the manuscript; A. C. Felix , A. V. de Paula, N. E.
329 Ferreira contributed to acquisition, analysis, and interpretation of data, critically revised
330 the manuscript; T. R. Tozetto-Mendoza contributed to conception of the study,
331 interpretation of data, critically revised the manuscript; R. A. V. Caixeta contributed to
332 analysis and interpretation of data, drafted the manuscript; F. E. Leal, R. M. Z. Grespan,
333 J. C. S. Bizário, A. B. C. Ferraz contributed to conception and study design, acquisition
334 of data, critically revised the manuscript; D. Sapkota, S. Giannecchini, K. K. To, A.

335 Doglio contributed to analysis and interpretation of data, drafted and critically revised the
336 manuscript. All authors gave their final approval and agree to be accountable for all
337 aspects of the work.

338

339 **Acknowledgements**

340 This study was supported by the Internal funding from the Hospital das Clínicas of the
341 University of São Paulo School of Medicine, São Paulo, Brazil. We would like to thank
342 José Tadeu Sales for the language correction of the manuscript. The authors declare no
343 potential conflict of interest with respect to the authorship and/or publication of this
344 article.

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360 **References**

- 361 1. Landry ML, Criscuolo J, Peaper DR. 2020. Challenges in use of saliva for detection
362 of SARS CoV-2 RNA in symptomatic outpatients. *J Clin Virol* 130:104567.
- 363 2. Yokota I, Shane PY, Okada K, Unoki Y, Yang Y, Inao T, Sakamaki K, Iwasaki S,
364 Hayasaka K, Sugita J, Nishida M, Fujisawa S, Teshima T. 2020. Mass screening of
365 asymptomatic persons for SARS-CoV-2 using saliva. *Clin Infect Dis*
366 doi:10.1093/cid/ciaa1388.
- 367 3. Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF,
368 Casanovas-Massana A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M,
369 Nelson A, Fournier J, Bermejo S, Campbell M, Datta R, Dela Cruz CS, Farhadian
370 SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB, Wyllie AL. 2020. Simply saliva:
371 stability of SARS-CoV-2 detection negates the need for expensive collection
372 devices. medRxiv doi:10.1101/2020.08.03.20165233.
- 373 4. Hall EW, Luisi N, Zlotorzynska M, Wilde G, Sullivan P, Sanchez T, Bradley H, Siegler
374 AJ. 2020. Willingness to Use Home Collection Methods to Provide Specimens for
375 SARS-CoV-2/COVID-19 Research: Survey Study. *J Med Internet Res* 22:e19471.
- 376 5. Valentine-Graves M, Hall E, Guest JL, Adam E, Valencia R, Shinn K, Hardee I,
377 Sanchez T, Siegler AJ, Sullivan PS. 2020. At-home self-collection of saliva,
378 oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and
379 serology: Post-collection acceptability of specimen collection process and
380 patient confidence in specimens. *PLoS One* 15:e0236775.
- 381 6. Therchilsen JH, von Buchwald C, Koch A, Dam Nielsen S, Rasmussen DB, Thudium
382 RF, Kirkby NS, Raaschou-Pedersen DET, Bundgaard JS, Iversen K, Bundgaard H,
383 Todsén T. 2020. Self-Collected versus Healthcare Worker-Collected Swabs in the

- 384 Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2. *Diagnostica*
385 (Basel) 10.
- 386 7. Tu YP, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, Verma P, Vojta D,
387 Berke EM. 2020. Swabs Collected by Patients or Health Care Workers for SARS-
388 CoV-2 Testing. *N Engl J Med* 383:494-496.
- 389 8. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir SM.
390 2020. Self-Collected Anterior Nasal and Saliva Specimens versus Healthcare
391 Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-
392 CoV-2. *J Clin Microbiol* doi:10.1128/JCM.01824-20.
- 393 9. Fernandes LL, Pacheco VB, Borges L, Athwal HK, de Paula Eduardo F, Bezinelli L,
394 Correa L, Jimenez M, Dame-Teixeira N, Lombaert IMA, Heller D. 2020. Saliva in
395 the Diagnosis of COVID-19: A Review and New Research Directions. *J Dent Res*
396 doi:10.1177/0022034520960070:22034520960070.
- 397 10. Sapkota D, Soland TM, Galtung HK, Sand LP, Giannecchini S, To KKW, Mendes-
398 Correa MC, Giglio D, Hasseur B, Braz-Silva PH. 2020. COVID-19 salivary signature:
399 diagnostic and research opportunities. *J Clin Pathol* doi:10.1136/jclinpath-2020-
400 206834.
- 401 11. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M,
402 Vijayakumar P, Warren JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone
403 ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M,
404 Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S,
405 Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park
406 A, Silva J, Song E, Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo
407 S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A,

- 408 Grubaugh ND, et al. 2020. Saliva or Nasopharyngeal Swab Specimens for
409 Detection of SARS-CoV-2. *N Engl J Med* 383:1283-1286.
- 410 12. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM,
411 Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW,
412 Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. 2020. Temporal
413 profiles of viral load in posterior oropharyngeal saliva samples and serum
414 antibody responses during infection by SARS-CoV-2: an observational cohort
415 study. *Lancet Infect Dis* 20:565-574.
- 416 13. Henrique Braz-Silva P, Pallos D, Gianecchini S, To KK. 2020. SARS-CoV-2: What
417 can saliva tell us? *Oral Dis* doi:10.1111/odi.13365.
- 418 14. Adeoye J, Thomson P. 2020. 'The Double-Edged Sword' - An hypothesis for Covid-
419 19-induced salivary biomarkers. *Med Hypotheses* 143:110124.
- 420 15. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. 2020. Substantial
421 undocumented infection facilitates the rapid dissemination of novel coronavirus
422 (SARS-CoV-2). *Science* 368:489-493.
- 423 16. Leal FE M-CM, Buss LF, et al. 2020. A primary care approach to the COVID-19
424 pandemic: clinical features and natural history of 2,073 suspected cases in the
425 Corona Sao Caetano programme, Sao Paulo, Brazil. *medRxiv*
426 doi:10.1101/2020.06.23.20138081
- 427 17. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G,
428 Sukswan W, Sungkanuparph S, Phuphuakrat A. 2020. Saliva sample as a non-
429 invasive specimen for the diagnosis of coronavirus disease 2019: a cross-
430 sectional study. *Clin Microbiol Infect* doi:10.1016/j.cmi.2020.05.001.

- 431 18. To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM, Leung WS, Chik TS, Choi CY,
432 Kandamby DH, Lung DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng VC, Chan JF,
433 Yuen KY. 2020. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin
434 Infect Dis 71:841-843.
- 435 19. Williams E, Bond K, Zhang B, Putland M, Williamson DA. 2020. Saliva as a
436 Noninvasive Specimen for Detection of SARS-CoV-2. J Clin Microbiol 58.
- 437 20. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, Fasano M,
438 Sessa F, Tettamanti L, Carinci F, Maurino V, Rossi A, Tagliabue A, Baj A. 2020.
439 Saliva is a reliable tool to detect SARS-CoV-2. J Infect 81:e45-e50.
- 440 21. Cheuk S, Wong Y, Tse H, Siu HK, Kwong TS, Chu MY, Yau FYS, Cheung IYY, Tse
441 CWS, Poon KC, Cheung KC, Wu TC, Chan JWM, Cheuk W, Lung DC. 2020. Posterior
442 oropharyngeal saliva for the detection of SARS-CoV-2. Clin Infect Dis
443 doi:10.1093/cid/ciaa797.
- 444 22. Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami
445 S, Barati S, Crowl G, Faheem A, Farooqi L, Khan S, Prost K, Poutanen S, Taylor M,
446 Yip L, Zhong XZ, McGeer AJ, Mubareka S, Toronto Invasive Bacterial Diseases
447 Network C-I. 2020. Sensitivity of nasopharyngeal swabs and saliva for the
448 detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin
449 Infect Dis doi:10.1093/cid/ciaa848.
- 450 23. Rao M, Rashid FA, Sabri F, Jamil NN, Zain R, Hashim R, Amran F, Kok HT, Samad
451 MAA, Ahmad N. 2020. Comparing nasopharyngeal swab and early morning saliva
452 for the identification of SARS-CoV-2. Clin Infect Dis doi:10.1093/cid/ciaa1156.
- 453 24. Xu J, Li Y, Gan F, Du Y, Yao Y. 2020. Salivary Glands: Potential Reservoirs for
454 COVID-19 Asymptomatic Infection. J Dent Res 99:989.

- 455 25. Kheur S, Kheur M, Gupta AA, Raj AT. 2020. Is the gingival sulcus a potential niche
456 for SARS-Corona virus-2? *Med Hypotheses* 143:109892.
- 457 26. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, Horiuchi M,
458 Kato K, Imoto Y, Iwata M, Mimura S, Ito T, Tamura K, Kato Y. 2020. Clinical
459 Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR
460 (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal
461 Amplification, and a Rapid Antigen Test To Diagnose COVID-19. *J Clin Microbiol*
462 58.
- 463 27. Weiss A, Jellingso M, Sommer MOA. 2020. Spatial and temporal dynamics of
464 SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis.
465 *EBioMedicine* 58:102916.
- 466 28. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, Xie G, Lin S, Wang R, Yang X, Chen W,
467 Wang Q, Zhang D, Liu Y, Gong R, Ma Z, Lu S, Xiao Y, Gu Y, Zhang J, Yao H, Xu K, Lu
468 X, Wei G, Zhou J, Fang Q, Cai H, Qiu Y, Sheng J, Chen Y, Liang T. 2020. Viral load
469 dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang
470 province, China, January-March 2020: retrospective cohort study. *BMJ*
471 369:m1443.
- 472 29. Samaranayake LP, Fakhruddin KS, Panduwawala C. 2020. Sudden onset, acute
473 loss of taste and smell in coronavirus disease 2019 (COVID-19): a systematic
474 review. *Acta Odontol Scand* 78:467-473.
- 475 30. Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, Chong S, Newcombe
476 JP, Siversten T, Hadlow N. 2020. Self-collection: An appropriate alternative
477 during the SARS-CoV-2 pandemic. *J Clin Virol* 128:104417.
- 478

479 **Table 1** - Comparison of SARS-CoV-2 RNA status in saliva and NOP samples in 201
480 patients undergoing testing for COVID-19.

| NOP | Saliva | |
|-----------------|-----------------|-----------------|
| | Negative | Positive |
| Negative | 131 | 18 |
| Positive | 15 | 37 |

481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501

502 **Table 2** - Demographic and clinical characteristics of 201 patients with suspected
503 COVID-19 tested with RT-PCR in both saliva and NOP samples.


| | NOP- /saliva- (G1) N = 131 n(%) or median (IQR) | NOP-/saliva+ (G2) N = 18 n(%) or median (IQR) | NOP+/saliva- (G3) N = 15 n(%) or median (IQR) | NOP+/saliva+ (G4) N = 37 n(%) or median (IQR) | P-value G3 vs G4 | P-value G2 vs G4 |
|---|---|---|---|---|----------------------------|----------------------------|
| Age | 40 (31 - 52) | 30 (29 - 49) | 32 (26 - 44) | 39 (30 - 48) | 0.312 | 0.907 |
| Gender | | | | | | |
| Male | 49 (62) | 2 (11) | 5 (33) | 18 (48.6) | 0.484 | 0.016 |
| Female | 81 (38) | 16 (89) | 10 (67) | 19 (51.4) | | |
| Delay between symptoms and collection (days) | 6 (4 - 9) | 6 (5 - 9) | 7 (5 - 8) | 4 (4 - 6) | 0.039 | 0.029 |
| Symptoms | | | | | | |
| Fever | 43 (33) | 6 (33) | 7 (47) | 19 (51) | 1.0 | 0.332 |
| Anosmia | 37 (28) | 8 (44) | 11 (79) | 18 (53) | 0.188 | 0.996 |
| Ageusia | 38 (29) | 7 (39) | 11 (73) | 13 (35) | 0.028 | 1.0 |
| Nasal congestion | 73 (56) 76 (58) | 11 (61) 7 (39) | 10 (67) 5 (33) | 29 (78) 19 (51) | 0.60 0.38 | 0.30 0.56 |
| Coryza | 88 (68) | 12 (66) | 9 (60) | 26 (70) | 0.697 | 0.1.0 |
| Myalgia | 62 (48) | 9 (50) | 7 (47) | 19 (51) | 1.0 | 1.0 |
| Arthralgia | 97 (75) | 12 (66) | 11 (73) | 30 (81) | 0.80 | 0.314 |
| Cough | | | | | | |

504
505 *Notes:* NOP- naso/oropharyngeal swab; G1 – group 1; G2 – group 2; G3 – group 3; G4 – group 4; IQR –
506 interquartile range.

507
508
509
510
511
512
513
514
515
516
517

518 **Figure 1**

519



520

521

522

523

524

525

526

527

528

529


530

531

532

533

534 **Figure 2**



535

536

537

538

539

540


541

542

543

544

545 **Figure 3**



546

547

548

549

550

551

552

553

554

555 **Figure Legends**

556

557 **Figure 1** - Comparison of RT-PCR cycle thresholds between naso-oropharyngeal and
558 saliva samples in 37 patients with positive results in both samples. The coefficients of the
559 regression lines are 0.79 ($P < 0.001$) for gene E and 0.74 ($P = 0.002$) for gene S.

560

561 **Figure 2**

562 **A** - Violin plots showing the distribution of cycle thresholds in nasal-oropharyngeal
563 swabs (NOP) and saliva samples for the two genes (E and S) amplified by RT-PCR.
564 Boxplots shows median, interquartile range and range as standard. Analysis of the 37
565 patients with positive results in both sample types by comparing the distributions of cycle
566 thresholds between NOP and saliva samples. Paired Wilcoxon's rank-sum test was used,
567 in which P -values were < 0.001 for genes E and S.

568 **B** - Distribution of SARS-CoV-2 RT-PCR cycle thresholds in the 52 positive nasal-
569 oropharyngeal swabs (NOP) samples stratified by RT-PCR results in saliva
570 (NOP+/saliva- versus NOP+/saliva+). Boxplots shows median, interquartile range and
571 range as standard. Distributions were compared by using paired Wilcoxon's rank-sum
572 test, in which P -values were 0.21 and 0.35 for genes E and S, respectively.

573

574 **Figure 3** - Relationship between illness course (i.e. time elapsed between symptom onset
575 and sample collection) and cycle threshold values for nasal-oropharyngeal swabs (NOP)
576 (left-hand panels) and saliva samples (right-hand panels). In the NOP samples, the
577 regression coefficients for cycle threshold (delay of \log_2 -days) for genes E and S were
578 0.5 ($P = 0.72$) and 1.1 ($P = 0.42$), respectively; the regression coefficients for saliva
579 samples were 0.04 ($P = 0.98$) and -0.26 ($P = 0.87$) for genes E and S, respectively.